Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -133.04M | -118.96M | -168.30M | -177.08M | -175.84M |
| Total Depreciation and Amortization | 3.21M | 4.39M | 5.71M | 6.41M | 7.12M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.28M | -54.86M | -14.35M | -128.00K | 4.27M |
| Change in Net Operating Assets | 236.00K | -6.28M | 366.00K | -3.96M | -24.13M |
| Cash from Operations | -176.87M | -175.71M | -176.57M | -174.76M | -188.58M |
| Capital Expenditure | -1.31M | -1.47M | -1.25M | -613.00K | -589.00K |
| Sale of Property, Plant, and Equipment | 65.39M | 65.39M | 0.00 | 1.25M | 1.25M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 102.93M | 78.65M | 100.99M | 109.40M | 117.57M |
| Cash from Investing | 167.00M | 142.57M | 99.74M | 110.04M | 118.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 122.00K | 118.00K | 47.00K | 34.00K | 33.00K |
| Repurchase of Common Stock | -3.00M | -6.00M | -6.00M | -3.00M | -3.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.00M | 48.00M | 48.00M | 45.00M | 45.00M |
| Cash from Financing | 122.00K | 42.12M | 42.05M | 42.03M | 42.03M |
| Foreign Exchange rate Adjustments | 3.00K | -4.00K | -29.00K | -99.00K | 9.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.75M | 8.98M | -34.81M | -22.79M | -28.31M |